The impact of Janus kinase 1 inhibitors on quality of life in patients with hidradenitis suppurativa

Hans Christian Ring; Simon F. Thomsen

doi:10.1111/bjd.21045

The impact of Janus kinase 1 inhibitors on quality of life in patients with hidradenitis suppurativa

Hans Christian Ring^*, Simon F. Thomsen

^*Corresponding author af dette arbejde

Inflammation, Metabolism and Oxidation

Publikation: Bidrag til tidsskrift › Letter › peer review

13 Downloads (Pure)

Originalsprog	Engelsk
Tidsskrift	British Journal of Dermatology
Vol/bind	187
Udgave nummer	2
Sider (fra-til)	274-274
ISSN	0007-0963
DOI	https://doi.org/10.1111/bjd.21045
Status	Udgivet - 2022

Bibliografisk note

Funding Information:
Conflicts of interest: H.C.R. has received research funding from the Kgl Hofbundtmager Aage Bang Foundation and honoraria as speaker from LEO Pharma. S.F.T. has been a speaker and/or served on advisory boards for AbbVie, Almirall, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi and UCB, and has received research support from AbbVie, Janssen, LEO Pharma, Novartis, Sanofi and UCB.

Adgang til dokumentet

10.1111/bjd.21045

FulltextAccepteret manuskript, 203 KB

Citationsformater

@article{9bc2558511af4f2b8ecc850b1abbeda3,

title = "The impact of Janus kinase 1 inhibitors on quality of life in patients with hidradenitis suppurativa",

author = "Ring, {Hans Christian} and Thomsen, {Simon F.}",

note = "Conflicts of interest: H.C.R. has received research funding from the Kgl Hofbundtmager Aage Bang Foundation and honoraria as speaker from LEO Pharma. S.F.T. has been a speaker and/or served on advisory boards for AbbVie, Almirall, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi and UCB, and has received research support from AbbVie, Janssen, LEO Pharma, Novartis, Sanofi and UCB.",

year = "2022",

doi = "10.1111/bjd.21045",

language = "English",

volume = "187",

pages = "274--274",

journal = "British Journal of Dermatology",

issn = "0007-0963",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - The impact of Janus kinase 1 inhibitors on quality of life in patients with hidradenitis suppurativa

AU - Ring, Hans Christian

AU - Thomsen, Simon F.

N1 - Conflicts of interest: H.C.R. has received research funding from the Kgl Hofbundtmager Aage Bang Foundation and honoraria as speaker from LEO Pharma. S.F.T. has been a speaker and/or served on advisory boards for AbbVie, Almirall, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi and UCB, and has received research support from AbbVie, Janssen, LEO Pharma, Novartis, Sanofi and UCB.

PY - 2022

Y1 - 2022

U2 - 10.1111/bjd.21045

DO - 10.1111/bjd.21045

M3 - Letter

C2 - 35122235

AN - SCOPUS:85129563325

SN - 0007-0963

VL - 187

SP - 274

EP - 274

JO - British Journal of Dermatology

JF - British Journal of Dermatology

IS - 2

ER -